查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926857

粘菌素甲磺酸盐注射液市场按适应症、剂型、患者群体、给药途径和最终用户划分－2026-2032年全球预测

Colistimethate Sodium for Injection Market by Indication, Dosage Form, Patient Population, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年粘菌素磺酸盐注射液市场价值为 5,054 万美元，预计到 2026 年将成长至 5,889 万美元，到 2032 年将达到 1.1043 亿美元，复合年增长率为 11.81%。

关键市场统计数据
基准年 2025 5054万美元
预计年份：2026年 5889万美元
预测年份 2032 1.1043亿美元
复合年增长率 (%) 11.81%

深入介绍注射甲磺酸盐钠：说明其临床应用、给药途径、製剂选择和患者照护环境

注射用硫酸粘菌素钠在现代感染疾病管理中扮演独特的角色，主要用于治疗难治性革兰氏阴性病菌感染。其药理特性和临床效用在多重抗药性限制第一线药物疗效的情况下尤其重要。硫酸粘菌素钠最初被视为最后一线治疗药物，但随着给药策略和方法的改进，以及对最容易获益患者群体的深入了解，其临床应用已日趋成熟。

抗菌素抗药性、综合管理、製剂创新以及对供应链韧性日益增长的期望，共同推动了变革性变革。

随着多种因素的共同作用，粘菌素甲磺酸钠的市场模式正在发生变化，这些因素正在改变临床实践、供应链和商业策略。抗生素抗药性的趋势仍然是主要的临床驱动因素，促使医生和医疗机构透过改进给药方案并在条件允许的情况下实施治疗药物监测来维持疗效。同时，抗菌药物管理计画（ASP）的角色正在从咨询安全隔离网闸，影响药物使用模式，并推广优化给药方案，例如在特定严重患者中使用持续输注，从而在最大限度提高动态暴露的同时降低毒性风险。

近期关税变化对无菌注射剂供应链、筹资策略、采购趋势和国内生产奖励的累积影响

关税制度和跨境贸易趋势的政策变化正对无菌注射剂供应链产生实际的影响，粘菌素钠也不例外。原料药、辅料和包装组件关税结构的调整增加了成品的到岸成本，促使生产者重新评估其筹资策略。随着进口成本的上升，采购团队和生产商会透过寻找替代供应商、转移生产或重新设计包装来应对关税上涨的影响。

透过细分市场洞察，揭示配方便利性、给药方式和患者人口统计特征等因素如何相互交织，进而影响临床和采购优先事项。

细分市场能够提供细緻的洞察，从而指导产品开发、临床应用和筹资策略。基于适应症的频谱涵盖范围广泛，从需要高度微生物学精准度的血流感染疾病（包括原发性和继发性菌血症）到下呼吸道感染疾病（包括社区获得性肺炎、医院获得性肺炎和人工呼吸器相关性肺炎，这些感染通常需要住院重症监护资源和复杂的给药技术）。皮肤和软组织感染疾病（包括蜂窝组织炎组织炎、手术部位感染和伤口感染）凸显了灵活给药策略的必要性，这些策略既适用于住院也适用于门诊病人。同时，尿道感染尿道感染（分为复杂性和非复杂性）则凸显了标靶药物管理和门诊治疗模式的机会。

影响美洲、欧洲、中东和非洲以及亚太地区临床应用、采购行为和生产重点的区域趋势

区域趋势将对粘菌素甲磺酸钠注射液的临床实践、法律规范和供应链策略产生重大影响。在美洲，医疗机构的抗菌药物管理框架和大规模综合医疗网络创造了一个以数据为导向、并与抗菌药物通讯协定紧密结合的环境。医院和专业输液中心重视抗菌药物管理的协调一致、临床医生教育和供应可靠性。合约机制和集团采购组织在采购中发挥重要作用，促使供应商在商业性谈判中优先考虑服务水准、交货保证和品质指标。

公司策略强调无菌生产卓越性、配方创新、伙伴关係模式和差异化商业服务，以赢得临床试验点和采购部门的信任。

硫酸粘菌素钠注射液市场的竞争格局由成熟的无菌注射剂生产商、非专利公司以及专注于无菌填充和包装的专业契约製造(CMO) 组成。现有生产商强调合规性、供应稳定性以及临床支援服务是其差异化优势，并投资于品质系统和审核准备工作，以满足医院的采购要求。同时，学名药生产商和小型供应商则在价格和区域分销方面竞争，同时面临维持无菌注射产品所需高品质标准的压力。

针对製造商和供应商的具体策略建议，以加强供应链韧性、扩大产品组合併深化临床伙伴关係。

产业领导者可以透过实施有针对性的策略行动，果断应对不断变化的市场环境。他们优先投资于无菌注射剂生产能力和品质体系，以减少对集中式供应链的依赖，并能够快速回应需求衝击。同时，他们利用多供应商策略和区域合作伙伴，实现活性成分和包装组件采购来源多元化，从而降低地缘政治和关税风险。

我们采用了稳健的混合调查方法，结合了对临床和采购相关人员的初步访谈、有针对性的文献综述、监管分析和资料检验。

本执行摘要的调查方法采用了一种三角测量法，结合了与主要相关人员的对话、有针对性的二手研究以及严格的资料检验。主要数据是透过与感染疾病医生、医院药剂师、采购负责人以及生产和监管专家进行结构化访谈和咨询收集的，旨在了解实际使用模式、采购需求和生产限制。这些对话有助于建立关键的临床应用案例，推荐给药方式，并识别与无菌注射剂生产和分销相关的营运挑战。

关键性综合分析强调了实现永续取得所需的供应韧性、製剂创新、管理协作以及有针对性的临床证据。

总之，注射用粘菌素钠仍是复杂临床环境下治疗严重革兰氏阴性菌病菌感染的重要治疗方法。抗菌药物抗药性的日益增强、抗菌药物管理计画的日益成熟以及医疗服务模式的不断变化，凸显了建立稳健的供应链、研发临床适用的製剂以及加强生产商与医疗服务提供者之间协作的重要性。儘管医院和加护病房仍然是需求中心，但门诊输液服务和专科诊所也不断扩展，为注射治疗提供更多选择。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 粘菌素甲磺酸盐注射液市场依适应症划分

  • 血液感染疾病
    • 原发性菌血症
    • 续发性菌血症
  • 下呼吸道感染疾病
    • 社区型肺炎
    • 院内肺炎
    • 人工呼吸器相关性肺炎
  • 皮肤和软组织感染疾病
    • 蜂窝组织炎
    • 手术部位感染
    • 伤口感染疾病
  • 尿道感染
    • 复杂性尿道感染
    • 单纯性尿道感染

9. 甲磺酸磺酸盐钠注射液市场（以剂型划分）

  • 冻干粉
    • 多剂量管瓶
    • 单剂量管瓶
  • 即用型解决方案
    • 点滴袋
    • 预填充式注射器

10. 依患者族群分類的甲磺酸磺酸盐钠注射液市场

  • 成人
  • 老年人
  • 儿童
    • 青春期
    • 儿童
    • 婴儿
    • 新生

11. 甲磺酸磺酸盐注射剂市场依给药途径划分

  • 吸入
  • 肌肉内注射
  • 静脉注射
    • 持续输注
    • 间歇输注

12. 依最终用户分類的甲磺酸磺酸盐钠注射液市场

  • 门诊治疗中心
  • 诊所
    • 门诊部
    • 专科部门
  • 医院
    • 普通病房
    • 加护病房

13. 各地区粘菌素甲磺酸盐注射液市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 注射用甲磺酸磺酸盐钠市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国粘菌素甲磺酸盐注射液市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国註射甲磺酸磺酸盐钠市场

17. 中国注射甲磺酸钠磺酸盐市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Pfizer Inc.
  • Sagent Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FF33A

The Colistimethate Sodium for Injection Market was valued at USD 50.54 million in 2025 and is projected to grow to USD 58.89 million in 2026, with a CAGR of 11.81%, reaching USD 110.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 50.54 million
Estimated Year [2026] USD 58.89 million
Forecast Year [2032] USD 110.43 million
CAGR (%) 11.81%

A detailed introduction to colistimethate sodium injections emphasizing clinical roles, administration pathways, formulation choices, and patient care settings

Colistimethate sodium for injection occupies a distinctive role in contemporary infectious disease management, primarily as a therapeutic option reserved for difficult-to-treat Gram-negative infections. Its pharmacological profile and clinical utility are particularly relevant in settings where multi-drug resistance limits the effectiveness of first-line agents. Historically positioned as a salvage therapy, colistimethate sodium has evolved in clinical practice through refinements in dosing strategies, administration modalities, and an expanded understanding of patient populations that derive the greatest benefit.

Clinically, its applications encompass a spectrum of severe infections including bloodstream infections, lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections. Within these indications, specific clinical presentations such as primary and secondary bacteremia; community-acquired, hospital-acquired, and ventilator-associated pneumonias; cellulitis, surgical site, and wound infections; and both complicated and uncomplicated urinary tract infections require nuanced therapeutic decision making. These distinctions drive differential needs for dosing regimens, monitoring parameters, and supportive care pathways.

From an administration standpoint, clinicians choose among inhalation, intramuscular, and intravenous routes, with intravenous delivery further stratified into continuous and intermittent infusion methods to optimize pharmacokinetic and pharmacodynamic targets. Formulation choices influence clinical workflows: lyophilized powders-available in multi-dose and single-dose vials-remain important for stability and cold-chain considerations, while ready-to-use solutions such as infusion bags and prefilled syringes are increasingly valued for workflow efficiency and reduced preparation error. End users range from ambulatory care centers and clinics, including outpatient and specialty clinic settings, to hospitals where general wards and intensive care units present the highest demand and the most complex administration scenarios. Patient populations span adult, geriatric, and pediatric cohorts, with pediatric care further delineated into adolescent, child, infant, and neonatal groups, each of which imposes specific dosing and safety imperatives.

Taken together, these clinical, formulation, and care-setting dimensions define the practical landscape in which product developers, hospital pharmacists, and policymakers operate. The interplay of antimicrobial stewardship priorities, evolving resistance patterns, and operational constraints within hospitals continues to shape how colistimethate sodium is prescribed, prepared, and administered in contemporary clinical practice.

Transformative shifts driven by antimicrobial resistance, stewardship integration, formulation innovation, and heightened supply chain resilience expectations

The landscape for colistimethate sodium is shifting under several convergent forces that are transforming clinical practice, supply chains, and commercial strategies. Antimicrobial resistance trends remain the primary clinical driver, compelling physicians and institutions to preserve efficacy by refining dosing algorithms and integrating therapeutic drug monitoring where feasible. Concurrently, antimicrobial stewardship programs have matured from advisory roles into active gatekeepers of formulary access, influencing utilization patterns and encouraging the use of optimized administration approaches such as continuous infusion in select critically ill patients to maximize pharmacodynamic exposure while reducing toxicity risk.

Technological and formulation advances are reshaping how injectable antibiotics are deployed in hospitals and ambulatory settings. The trend toward ready-to-use solutions supports faster bedside administration and reduces compounding risk, which is particularly attractive in high-acuity units and outpatient infusion centers. Simultaneously, renewed interest in inhalation delivery for respiratory infections highlights the clinical community's willingness to explore localized therapies that may deliver higher pulmonary concentrations with potentially reduced systemic exposure. These therapeutic shifts are paralleled by manufacturing innovations, including improvements in sterile injectable production, packaging that extends product stability, and processes that enable smaller batch sizes to serve niche indications.

On the commercial front, supply chain resilience has moved to the forefront of strategic planning. Fabrication of active pharmaceutical ingredients, the geographic concentration of sterile injectable facilities, and regulatory inspections all influence product availability. As a result, organizations are increasingly prioritizing supplier diversification, on-site quality assurance, and partnerships with contract manufacturing organizations to mitigate disruption risk. Regulatory and procurement environments are evolving too; payers and hospital group purchasing organizations are applying more rigorous evaluation criteria tied to product risk management and lifecycle support. Consequently, companies that align clinical evidence generation, formulation convenience, and supply reliability are positioned to achieve greater acceptance among clinicians and procurement stakeholders.

Finally, patient-centric care models and the expansion of outpatient parenteral antimicrobial therapy are changing where treatments are delivered. With appropriate safety nets and training, selected indications historically managed in inpatient settings are now treated in ambulatory care centers or specialty clinics, reshaping demand profiles across care settings and accelerating the need for formulations that balance stability, ease of administration, and safety.

Cumulative effects of recent tariff shifts on supply chains, sourcing strategies, purchasing dynamics, and domestic manufacturing incentives for sterile injectables

Policy changes in tariff regimes and cross-border trade dynamics have tangible operational consequences for the supply chain of sterile injectables, and colistimethate sodium is not immune to these pressures. Alterations in tariff structures for active pharmaceutical ingredients, excipients, and packaging components can increase landed costs for finished product and create incentives for manufacturers to reassess sourcing strategies. When import costs rise, procurement teams and manufacturers respond by exploring alternative suppliers, shifting production footprints, or reconfiguring packaging to reduce exposure to tariff escalations.

The cumulative effects of tariff adjustments reverberate through contract negotiations, inventory strategies, and capital allocation. Healthcare providers and group purchasing entities may face higher acquisition costs, which in turn prompts more stringent tender evaluations and a greater emphasis on contractual guarantees for supply continuity. Manufacturers facing higher input costs often evaluate whether to absorb marginal increases, adjust list pricing, or renegotiate distribution agreements. In some cases, tariff volatility accelerates investment in onshore or near-shore production capabilities to mitigate future trade-policy risk and secure critical sterile manufacturing capacity.

From a clinical operations perspective, tariff-driven cost pressures can influence formulary decisions and the prioritization of stewardship interventions. Hospitals may intensify utilization review for high-cost injectables, seek therapeutic alternatives where clinically appropriate, or consolidate purchasing across health systems to restore negotiating leverage. For small suppliers and generic players, higher import duties may constrain margins and impede the ability to scale sterile production, potentially reducing competition over time and increasing dependence on a narrower set of suppliers.

In sum, changes in tariff policy reverberate across commercial and clinical domains: they affect sourcing strategies, contractual dynamics, and the incentives to invest in domestic manufacturing. Stakeholders who proactively map tariff exposure, diversify supplier bases, and engage in scenario planning will be better positioned to maintain supply continuity and preserve therapeutic options for patients reliant on colistimethate sodium injections.

Segmentation insights revealing where formulation convenience, administration modality, and patient cohort specificity converge to shape clinical and procurement priorities

Segmentation drives nuanced insights that inform product development, clinical adoption, and procurement strategies. Based on indication, the spectrum spans bloodstream infections-where primary and secondary bacteremia presentations demand heightened microbiological precision-and lower respiratory tract infections, including community-acquired, hospital-acquired, and ventilator-associated pneumonias that often require inpatient critical care resources and advanced delivery methods. Skin and soft tissue infections, encompassing cellulitis, surgical site infections, and wound infections, highlight the need for flexible dosing strategies suitable for both inpatient and outpatient management, whereas urinary tract infections, differentiated into complicated and uncomplicated cases, underscore opportunities for targeted stewardship and outpatient therapy models.

When examined through the lens of route of administration, intravenous delivery remains pivotal in acute care, with continuous infusion increasingly employed to meet pharmacodynamic goals in critically ill patients while intermittent infusion retains relevance where nursing workflows and monitoring frameworks favor established practice patterns. Inhalation delivery presents a complementary strategy for pulmonary infections, offering localized drug delivery that can be particularly relevant in mechanically ventilated patients, while intramuscular options are less prominent but important in resource-constrained scenarios or settings without IV access.

Formulation segmentation reveals competing priorities between stability and convenience. Lyophilized powders, offered in multi-dose and single-dose vials, continue to be valued for shelf life and transport resilience, particularly in settings lacking sophisticated cold-chain infrastructure, whereas ready-to-use solutions in infusion bags and prefilled syringes reduce preparation time and compounding risk, improving safety and throughput in busy infusion units and ambulatory centers.

End-user segmentation points to hospitals-especially intensive care units and general wards-as primary centers of clinical demand, where high acuity drives immediate need for reliable sterile supplies and robust clinical support. Clinics, including outpatient and specialty clinics, are expanding their role through outpatient parenteral antimicrobial therapy programs that shift certain treatment episodes out of the hospital. Ambulatory care centers similarly contribute to demand growth for formulations that support safe home or clinic administration.

Patient population segmentation emphasizes differentiated clinical needs: adults and geriatric patients often present with comorbidities and altered pharmacokinetics requiring careful monitoring, while pediatric care, spanning adolescents, children, infants, and neonates, introduces additional complexity in dosing calculations, safety monitoring, and formulation tolerability. These patient distinctions necessitate tailored clinical evidence, dosing guidance, and packaging that supports safe use across the lifespan.

Synthesizing these segmentation layers reveals where product innovation and commercial focus can have the greatest impact: formulations that reconcile stability with administration efficiency, dosing strategies that account for special populations, and supply models that align with the procurement realities of high-acuity hospitals and expanding outpatient infusion services.

Regional dynamics shaping clinical adoption, procurement behaviors, and manufacturing priorities across the Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics materially influence clinical practice, regulatory oversight, and supply-chain strategies for colistimethate sodium injections. In the Americas, institutional stewardship frameworks and large integrated delivery networks create environments where formulary decisions are data driven and closely tied to antimicrobial protocols; hospitals and specialty infusion centers place a premium on stewardship alignment, clinician education, and supply reliability. Contracting mechanisms and group purchasing organizations play influential roles in procurement, prompting suppliers to prioritize service levels, delivery guarantees, and quality metrics in commercial discussions.

In Europe, the Middle East, and Africa, heterogeneity in regulatory regimes and healthcare financing models produces a mosaic of adoption patterns. Certain jurisdictions emphasize centralized procurement and stringent regulatory oversight, encouraging the uptake of well-documented generics and formulations that meet high standards for sterility and stability. In contrast, regions with constrained infrastructure may rely more heavily on lyophilized forms that tolerate variable storage conditions. Across these territories, public health initiatives and regional antimicrobial resistance programs inform utilization and access strategies.

The Asia-Pacific region presents a complex interplay of high infectious disease burden, variable regulatory maturity, and substantial manufacturing capacity. The prevalence of multi-drug-resistant organisms in several countries drives intensive clinical use in hospitals and ICUs, while strong pharmaceutical manufacturing ecosystems support both active pharmaceutical ingredient production and finished sterile injectable manufacturing. These capabilities create opportunities for localized production and export, but they also mean that policy shifts-such as tariffs or import controls-can rapidly alter global supply flows. Emerging outpatient care models in urban centers and increased investment in hospital infrastructure further shape demand for ready-to-use formulations and reliable sterile supply chains.

Across regions, differences in clinical practice, procurement frameworks, and manufacturing capacity determine where companies should focus evidence generation, formulation development, and commercial support. Understanding these regional nuances is essential for aligning product portfolios with the operational realities and clinical priorities of diverse healthcare systems.

Company strategies emphasizing sterile manufacturing excellence, formulation innovation, partnership models, and commercial service differentiation to secure clinical and procurement trust

Competitive dynamics in the injectable colistimethate sodium space reflect a blend of established sterile injectable manufacturers, generic players, and specialized contract manufacturers focused on sterile fill-finish capabilities. Established manufacturers emphasize regulatory compliance, consistent supply, and clinical support services as differentiators, investing in quality systems and audit readiness to meet hospital procurement expectations. Generics and smaller suppliers often compete on price and regional distribution strength, while facing pressure to maintain the high quality standards required for sterile injectable products.

Strategic behavior among companies includes investment in ready-to-use formats to capture hospital preference for reduced compounding risk, partnerships with contract manufacturing organizations to scale sterile capacity without excessive capital expenditure, and selective geographic expansion into regions with high clinical need or manufacturing synergies. Lifecycle management strategies are also prominent: suppliers pursue incremental innovations such as improved stability packaging, prefilled syringe platforms, and patient-centric dosing aids that streamline administration in outpatient or home settings.

Mergers, acquisitions, and strategic alliances are deployed to secure access to critical sterile capacity, particularly where barrier-to-entry costs and regulatory expectations are substantial. Supply reliability has become a commercial offering in itself, with companies differentiating on guaranteed fill rates, expedited logistics, and integrated quality reporting to procurement partners. Additionally, firms are increasingly investing in clinical education and stewardship engagement to support appropriate use and to build trust with institutional customers.

Taken together, these company-level priorities underline a clear imperative: success hinges on the ability to combine regulatory rigor, manufacturing resilience, clinically relevant formulation innovation, and proactive commercial support that addresses the operational pain points of hospitals and outpatient infusion providers.

Actionable strategic recommendations for manufacturers and providers to strengthen supply resilience, advance formulation portfolios, and deepen clinical partnerships

Industry leaders can respond decisively to the evolving landscape by implementing a focused set of strategic actions. Prioritize investment in sterile injectable manufacturing capacity and quality systems to reduce reliance on concentrated supply chains and enable faster responses to demand shocks. Concurrently, diversify sourcing of active pharmaceutical ingredients and packaging components, employing multi-vendor strategies and regional partners to lower geopolitical exposure and tariff risk.

Develop and accelerate ready-to-use formulations while maintaining lyophilized options for markets with cold-chain or stability constraints. By offering a portfolio that balances stability with administration efficiency, companies can address the needs of intensive care units, ambulatory infusion centers, and outpatient parenteral therapy programs. Pair formulation advances with clinical evidence generation tailored to special populations, including geriatrics and pediatric subgroups, to ensure prescriber confidence and to meet regulatory expectations in diverse jurisdictions.

Engage proactively with antimicrobial stewardship committees, hospital pharmacists, and physician champions to co-design educational programs, dosing guidelines, and therapeutic monitoring protocols. These collaborations will facilitate appropriate use, reduce potential toxicity concerns, and reinforce the supplier's role as a clinical partner rather than a vendor. On the commercial side, negotiate service-level agreements that emphasize supply guarantees, expedited logistics, and post-sale technical support to meet the procurement priorities of large health systems and group purchasing organizations.

Finally, embed tariff and regulatory scenario planning into commercial strategy. Model the implications of trade policy shifts on landed costs, and evaluate the feasibility of near-shore production or strategic stockpiles where clinically appropriate. These measures, combined with targeted investment in formulation innovation and stakeholder engagement, will strengthen resilience and create competitive differentiation that supports long-term access to this critical injectable therapy.

Robust mixed methods research approach combining primary clinical and procurement interviews, targeted literature review, regulatory analysis, and data triangulation

The research methodology underpinning this executive summary employed a triangulated approach combining primary stakeholder engagement, targeted secondary research, and rigorous data validation. Primary inputs were obtained through structured interviews and consultations with infectious disease clinicians, hospital pharmacists, procurement officers, and manufacturing and regulatory experts to capture real-world practice patterns, procurement imperatives, and manufacturing constraints. These conversations informed the framing of key clinical use cases, preferred administration modalities, and the operational challenges associated with sterile injectable production and distribution.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, public policy releases, and quality-assurance standards relevant to sterile injectable manufacturing and antimicrobial stewardship. Where applicable, company disclosures, product labeling, and public inspection reports were analyzed to corroborate claims about formulation attributes and manufacturing footprints. Regulatory databases were reviewed to understand approval pathways and post-market surveillance dynamics that affect clinical adoption.

Methodological rigor was maintained through cross-validation of primary and secondary findings, scenario analysis to assess the impact of trade and tariff changes, and sensitivity checks on supply chain assumptions. Stakeholder feedback loops ensured that interpretations of clinical practice and procurement behavior accurately reflected operational realities. Limitations of the methodology include variability in regional reporting standards and the inherent lag between guideline updates and bedside practice change, which were mitigated by prioritizing recent expert interviews and contemporaneous regulatory materials.

Ethical standards and confidentiality protocols were observed during primary data collection, and proprietary information shared by interviewees was handled in accordance with agreed non-disclosure terms. This mixed-methods approach yields a robust synthesis of clinical, commercial, and regulatory factors that inform practical decision making.

Conclusive synthesis highlighting the need for supply resilience, formulation innovation, stewardship collaboration, and targeted clinical evidence for sustained access

In conclusion, colistimethate sodium for injection remains an essential therapeutic tool for addressing severe Gram-negative infections in complex clinical settings. The interplay of rising antimicrobial resistance, maturation of stewardship programs, and changing care delivery models underscores the need for resilient supply chains, clinically relevant formulations, and collaborative engagement between manufacturers and healthcare institutions. Hospitals and intensive care units continue to be focal points of demand, while outpatient infusion services and specialty clinics are expanding the contexts in which injectable therapy is delivered.

Commercially, companies that invest in sterile manufacturing excellence, diversify sourcing, and offer formulations that align with frontline workflow imperatives will be best positioned to meet institutional needs. Regulatory and tariff environments add layers of complexity that require proactive scenario planning and potential near-shore capacity investments. From a clinical standpoint, tailored dosing guidance and evidence generation for special populations will be critical to ensure safe, effective, and guideline-concordant use across the lifespan.

Overall, the strategic priorities are clear: strengthen supply resilience, innovate in formulation and delivery to reduce compounding risk, and partner closely with stewardship programs and procurement stakeholders to secure appropriate, sustainable access to this vital injectable therapy. Acting on these imperatives will help preserve therapeutic options for patients facing severe, hard-to-treat infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colistimethate Sodium for Injection Market, by Indication

  • 8.1. Bloodstream Infection
    • 8.1.1. Primary Bacteremia
    • 8.1.2. Secondary Bacteremia
  • 8.2. Lower Respiratory Tract Infection
    • 8.2.1. Community Acquired Pneumonia
    • 8.2.2. Hospital Acquired Pneumonia
    • 8.2.3. Ventilator Associated Pneumonia
  • 8.3. Skin And Soft Tissue Infection
    • 8.3.1. Cellulitis
    • 8.3.2. Surgical Site Infection
    • 8.3.3. Wound Infection
  • 8.4. Urinary Tract Infection
    • 8.4.1. Complicated Urinary Tract Infection
    • 8.4.2. Uncomplicated Urinary Tract Infection

9. Colistimethate Sodium for Injection Market, by Dosage Form

  • 9.1. Lyophilized Powder
    • 9.1.1. Multi Dose Vial
    • 9.1.2. Single Dose Vial
  • 9.2. Ready To Use Solution
    • 9.2.1. Infusion Bag
    • 9.2.2. Prefilled Syringe

10. Colistimethate Sodium for Injection Market, by Patient Population

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric
    • 10.3.1. Adolescent
    • 10.3.2. Child
    • 10.3.3. Infant
    • 10.3.4. Neonatal

11. Colistimethate Sodium for Injection Market, by Route Of Administration

  • 11.1. Inhalation
  • 11.2. Intramuscular
  • 11.3. Intravenous
    • 11.3.1. Continuous Infusion
    • 11.3.2. Intermittent Infusion

12. Colistimethate Sodium for Injection Market, by End User

  • 12.1. Ambulatory Care Center
  • 12.2. Clinic
    • 12.2.1. Outpatient Clinic
    • 12.2.2. Specialty Clinic
  • 12.3. Hospital
    • 12.3.1. General Ward
    • 12.3.2. Intensive Care Unit

13. Colistimethate Sodium for Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Colistimethate Sodium for Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Colistimethate Sodium for Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Colistimethate Sodium for Injection Market

17. China Colistimethate Sodium for Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott
  • 18.6. Fresenius Kabi AG
  • 18.7. Gland Pharma Limited
  • 18.8. Hikma Pharmaceuticals PLC
  • 18.9. Lupin Limited
  • 18.10. Pfizer Inc.
  • 18.11. Sagent Pharmaceuticals, Inc.
  • 18.12. Sandoz International GmbH
  • 18.13. Teva Pharmaceutical Industries Ltd.
  • 18.14. Viatris Inc.
  • 18.15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY